Predicting of fentanyl-associated neurotoxicity in pancreatic cancer with clical, genetic model

Aim. To develop a model for the implementation of opioid - associated neurotoxicity in patients with pancreatic cancer based on an analysis of the relationship of clinical and genetic factors. Materials and methods. In 45 patients with pancreatic cancer, 54 clinical and genetic factors were studied for predicting the implementation of opioid-associated neurotoxicity, receiving a transdermal form of fentanyl. Results. A clinical genetic model of the implementation of opioid - associated neurotoxicity in patients with pancreatic cancer was developed using the example of a transdermal form of fentanyl Conclusion. The clinical genetic model for predicting the risk of opioid-associated neurotoxicity in patients with pancreatic cancer is important from the perspective of personalized medicine.

fentanyl TTS, neurotoxicity, sedation, pharmacogenetics, modeling, opioids, pancreatic cancer

1. Pchelincev M. V. Kliniko - farmakologicheskie osobennosti i preimushchestva transdermal’nogo primeneniya fentanila pri sil’noj hronicheskoj boli. [Clinical and pharmacological features and advantages of transdermal fentanyl for severe chronic pain]. Lechashchij vrach. 201, no. 5, pp. 2-7. (In Russ.)@@ Пчелинцев М. В. Клинико - фармакологические особенности и преимущества трансдермального применения фентанила при сильной хронической боли. Лечащий врач. - 201. - № 5. С. 2-7.

2. Kokubun H., Ebinuma K., Matoba M. еt al. Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. J Pain Palliat Care Pharmacother. 2012, no.26, pp. 98-104. doi: 10.3109/15360288.2012.679725.

3. Koulouris A. I., Banim P., Hart A. R. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments DigDisSci. 2017;62(4):861-870. doi: 10.1007/s10620-017-4488-z.

4. Barratt D. T., Bandak B., Klepstad P. еt al. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics. 2014, no.24, pp. 185-94. doi: 10.1097/ fpc.0000000000000032.

5. Nasyrova R. F., Sivakova N. A., Lipatova L. V., Ivashchenko D. V., Sosina K. A., Drokov A. P., Shnayder N. A. Biological markers of the antiepileptic drugs efficacy and safety: pharmacogenetics and pharmacokinetics. Siberian Medical Review. 2017; (1): 17-25. (In Russ.) DOI: 10.20333/2500136-2017-1-17-25.@@ Насырова Р. Ф., Сивакова Н. А., Липатова Л. В. и соавт. Биологические маркеры эффективности и безопасности противоэпилептических препаратов: фармакогенетика и фармакокинетик. Сибирское медицинское обозрение. - 2017. - № 1. - С. 17-25. doi: 10.20333/2500136-2017-1-17-25.

6. Pchelincev M. V., Abuzarova G. R. Transdermal’nye terapevticheskie sistemy s fentanilom pri hronicheskoj boli. Vrach. 2011, no. 6, pp. 39-42. (In Russ.)@@ Пчелинцев М. В., Абузарова Г. Р. Трансдермальные терапевтические системы с фентанилом при хронической болию Врач. - 2011. - № 6. - С. 39-42.

7. Sidorov A. V. Transdermal fentanyl: pharmacological aspects of therapy in cancer patients. Part 2. Application features of transdermal fentanyl formulations. Russian Journal of Oncology. 2017;22 (5):238-245. (In Russ.) Doi: 10.18821/1028-9984-2017-22-5-238-245@@ Сидоров А. В. Трансдермальные формы фентанила: фармакологические аспекты терапии онкологических пациентов. Часть 2. Особенности применения трансдермальных форм фентанила. Российский онкологический журнал. - 2017. - 22 (5). - С. 238-245. doi: 10.18821/1028-9984-2017-22-5-238-245.

8. Byval’cev V. A., Stepanov I. A., Belyh E. G., Yarullina A. I. The role of tumor stem cells in the development of brain gliomas. Sibirskoe medicinskoe obozrenie. 2015, no.6, pp. 5-14. (In Russ.)@@ Бывальцев В. А., Степанов И. А., Белых Е. Г., Яруллина А. И. Роль опухолевых стволовых клеток в развитии глиом головного мозга. Сибирское медицинское обозрение. - 2015. - № 6. - С. 5-14

9. Brock C., Olesen S. S., Olesen A. E. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72(14):1847-1865. Doi: 10.2165/11634970-000000000-00000

10. Kesimci E, Engin AB, Kanbak O, Karahalil B. Association between ABCB1 gene polymorphisms and fentanyl’s adverse effects in Turkish patients undergoing spinal anesthesia. Gene. 2012;493(2):273-277. doi:10.1016/j.gene.2011.11.040

11. Ding Z., Yang L., Xie X. et al. Expression and significance of hypoxiainducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. Cancer Res Clin Oncol. 2010, no. 3, pp. 1276-1282. doi: 10.1007/s00432-010-0828-5